论文部分内容阅读
目的:了解我院采用恩替卡韦片对乙肝患者健康状况影响。方法:乙肝患者治疗组是使用恩替卡韦片进行治疗,对照组采用拉米夫定治疗。结果:乙肝患者恩替卡韦片组与对照组血清标志物HBeAg、HBV-DNA、HBsAg浓度有差异(P<0.05)。恩替卡韦片对乙肝患者治疗效果明显有效(P<0.01)。乙肝患者预后健康状况相关因素包括患者营养状况、病理学分型、规范治疗、不良生活习惯和合并其它疾病等。结论:恩替卡韦片联合美能片是治疗乙肝患者治疗安全有效的药物。
Objective: To understand the influence of entecavir tablets on the health status of patients with hepatitis B in our hospital. Methods: Hepatitis B patients treated with entecavir tablets for treatment, the control group treated with lamivudine. Results: The serum HBeAg, HBV-DNA and HBsAg concentrations of entecavir group and control group were significantly different (P <0.05). Entecavir tablets treatment of patients with hepatitis B was effective (P <0.01). The prognosis of hepatitis B patients related to health status, including nutritional status of patients, pathological type, standardized treatment, unhealthy habits and other diseases combined. Conclusion: Entecavir Tablets combined with Minolta Tablets is a safe and effective drug for the treatment of hepatitis B patients.